socalTECH

JULY 15, 2019

Thousand Oaks-based Amgen , along with partners Novartis and the Banner Alzheimer's Institute , said late last week that they are discontinuing a clinical research program, which had focused on Alzheimer's prevention. READ MORE>>.

Study 113

Study Thousand Oaks Research Develop 113

socalTECH

MARCH 21, 2016

Thousand Oaks-based Amgen reports that it saw positive top-line results for a study for its romosozumab compound in men with osteoporosis. Amgen said its Phase 3 study demonstrated a significant increase in bone mineral density (BMD) at the lumbar spine, compared with a placebo over 12 months.

Study 100

Study Thousand Oaks Report Develop 100

socalTECH

SEPTEMBER 1, 2016

Thousand Oaks-based Amgen and Boehringer Ingelheim said on Thursday that Amgen has acquired the global development and commercial rights for an immuno-oncology drug for treating multiple myeloma. The compound is currently in Phase I studies. Financial details of the deal were not announced. READ MORE>>.

Thousand Oaks 113

Thousand Oaks Study Develop Development 113

socalTECH

AUGUST 9, 2012

Thousand Oaks-based Amgen said late Wednesday that it has terminated a Phase 3 study of a drug it is developing to treat metastatic pancreatic cancer, after a recommendation by the independent committee overseeing the trial.

Thousand Oaks 124

Thousand Oaks Statistics Study Develop 124

socalTECH

SEPTEMBER 25, 2013

Thousand Oaks-based biotech Amgen has linked with a university in Shanghai, China, to open up a new R&D center. According to Amgen, it has entered into a strategic partnership with ShanghaiTech University , to open up a research and development center at the university''s campus. READ MORE>>.

Thousand Oaks 113

Thousand Oaks Research Study Develop 113

Xconomy

SEPTEMBER 30, 2016

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

JUNE 10, 2016

—More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga. —On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67